✦ LIBER ✦

9003 ORAL Biomarker Analysis in BO21015, a Phase II Randomised Study of First-line Bevacizumab (BEV) Combined With Carboplatin-gemcitabine (CG) or Carboplatin-paclitaxel (CP) in Patients (pts) With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)

✍ Scribed by Mok, T.; Gorbunova, V.; Juhasz, E.; Szima, B.; Burdaeva, O.; Yu, C.J.; Delmar, P.; Pallaud, C.; Jonnaert, M.; Reck, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized phase II study of first-line

✍ Niho, Seiji; Kunitoh, Hideo; Nokihara, Hiroshi; Horai, Takeshi; Ichinose, Yukito 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 408 KB

6509 ORAL Management of hypertension (HT

✍ Bennouna, J.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 60 KB

A phase 1 study of linifanib in combinat

✍ Horinouchi, Hidehito; Yamamoto, Noboru; Nokihara, Hiroshi; Horai, Takeshi; Nishi 📂 Article 📅 2014 🏛 Springer 🌐 English ⚖ 417 KB

9172 Analysis of biomarkers (BMs) in the

✍ Leighl, N.; Reck, M.; de Haas, S.; Evers, S.; Delmar, P.; Manegold, C.; Scherer, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 49 KB

A phase I/randomized phase II, non-compa

✍ Roger B. Cohen; Corey J. Langer; George Rajan Simon; Peter David Eisenberg; John 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 387 KB

6503 ORAL Efficacy and safety results fr

✍ Manegold, C.; vonPawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB